Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients

In this exploratory population, the combination of an adequate CMV T-cell assay with adequate ALC was strongly predictive of no CMV reactivation. Further investigation into the predictive characteristics of a CMV T-cell assay combined with ALC and other patient-specific factors may optimize its clinical application.